Meletios-Athanassios Dimopoulos, MD, from the Athens School of Medicine, Athens, Greece, discusses appropriate treatments for patients with myeloma kidney disease. He especially highlights those presenting a need of renal dialysis, in these particular patients, there is a fifty percent probability that when they receive treatment with bortezomib based regimens, they will become independent of dialysis. Data was also presented regarding real world activity of pomalidomide and dexamethasone in patients who are resistant to lenalidomide and bortezomib, the data was able to show that the activity of this nation is approximately thirty percent in patients who are refractory to lenalidomide. Finally, Dr. Dimopoulos mentions some data presented on patients with waldenstrom globulinemia, treated with different regimens that they are working towards developing a revised staging system for patients with this disease. Recorded at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.